Prescribed List (Jersey): Changes from 1st November 2019

Information about the publication of Ministerial Decisions

A formal published “Ministerial Decision” is required as a record of the decision of a Minister (or an Assistant Minister where they have delegated authority) as they exercise their responsibilities and powers.

Ministers are elected by the States Assembly and have legal responsibilities and powers as “corporation sole” under the States of Jersey Law 2005 by virtue of their office and in their areas of responsibility, including entering into agreements, and under any legislation conferring on them powers.

An accurate record of “Ministerial Decisions” is vital to effective governance, including:

demonstrating that good governance, and clear lines of accountability and authority, are in place around decisions-making – including the reasons and basis on which a decision is made, and the action required to implement a decision
providing a record of decisions and actions that will be available for examination by States Members, and Panels and Committees of the States Assembly; the public, organisations, and the media; and as a historical record and point of reference for the conduct of public affairs

Ministers are individually accountable to the States Assembly, including for the actions of the departments and agencies which discharge their responsibilities.

The Freedom of Information Law (Jersey) Law 2011 is used as a guide when determining what information is be published. While there is a presumption toward publication to support of transparency and accountability, detailed information may not be published if, for example, it would constitute a breach of data protection, or disclosure would prejudice commercial interest.

A decision made on 25 October 2019

Decision Reference: MD-S-2019-0085
Decision Summary Title :	DS Prescribed list as of 1 Nov 2019		Date of Decision Summary:	23 October 2019
Decision Summary Author:	Policy Principal		Decision Summary: Public or Exempt?	Public
Type of Report: Oral or Written?	Written		Person Giving Oral Report:	NA
Written Report Title :	WR report PBAC 19 September 2019		Date of Written Report:	22 October 2019
Written Report Author:	Prescribing Advisor		Written Report : Public or Exempt?	Public
Subject: Changes to be made to the Prescribed List (Jersey) as of 1 November 2019
Decision(s): Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, and having consulted with the Pharmaceutical Benefit Advisory Committee, the Minister decided to make amendments to the Prescribed List with effect from 1 November 2019 as set out in the accompanying report and supporting document.
Reason(s) for Decision: The Pharmaceutical Benefit Advisory Committee met on 19 September 2019 and has provided the Minister with recommendations regarding amendments to the Prescribed List. Items to be added to the Prescribed List Semaglutide 1.34mg/mL solution for injection pre-filled devices Azelastine hydrochloride 125 micrograms/fluticasone propionate 50 micrograms nasal spray (Dymista brand) Hydrocortisone 500mcg/1mg/2mg/5mg granules in capsules for opening (Alkindi) for children Tiotropium 2.5microgram inhalation solution cartridge; tiotropium 2.5microgram/olodaterol 2.5mcg inhalation solution cartridge Following the meeting, the PBAC was asked to urgently consider changes to the Prescribed List in response to the Supply Disruption Alert for ranitidine (a treatment for stomach ulcers and acid reflux) issued on 16th October. Using its agreed procedure, the Committee recommends addition of the following product to provide an alternative to ranitidine while it is out of stock: Nizatidine 150mg capsules The recommendations reflect current evidence and expert advice, and ensure that patients in Jersey have access to an appropriate range of modern, safe and effective treatments from their GPs and community prescribers at a proportionate cost to the Fund. Other changes to the Prescribed List Further minor amendments and deletions will be made to the Prescribed List following a line by line review of the List and its reformatting to comply with dm+d nomenclature as requested by NHS Business Services Authority.
Resource Implications: The overall financial impact of the above changes is expected to be a small increase in total annual expenditure. One of the additions to the List has a commercial in confidence price, therefore the exact figure has not been published.
Action required: Health Zone Manager at Customer and Local Services to issue a public notice listing amendments and notify all approved medical practitioners and approved contractors.
Signature:		Position: Minister
Date Signed:		Date of Decision (If different from Date Signed):